Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: A clinical case with literature review
|
|
- Blaise Moody
- 6 years ago
- Views:
Transcription
1 Journal of BUON 11: , Zerbinis Medical Publications. Printed in Greece CSE REPORT Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: clinical case with literature review E. Piperkova 1, B. Raphael 2, M. ltinyay 2, I. Castellon 2, R. Libes 2, N. Sandella 2, H. bdel-dayem 2 1 Clinic of Nuclear Medicine, National Oncology Center Hospital, Sofi a, Bulgaria; 2 Department of Nuclear Medicine and Radiology, St. Vincent s Hospital and Cancer Center, New York Medical College, New York, US Summary Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCC) and survival depends on the treatment strategy. Exact staging leads to optimal planning of multimodality therapy and the adequate evaluation of treatment response can improve the prognosis of the disease. Diagnosis and staging of SCC are commonly performed using contrastenhanced computerized tomography (CT) and interpretation of the fi ndings are based on anatomical size criteria with limitations for tumor biological behavior. F18-fluoro-2 deoxy-d glucose positron emission tomography ( 18 F-FDG PET) reveals aspects of tumor function and allows metabolic measurements. Combined PET/CT scans permit exact localization with anatomical criteria of the hypermetabolic 18 F-FDG avid malignant lesions. We present a patient with SCC in whom, according to PET/CT fi ndings, the initial stage was changed from II (T2N0M0) to III (T2N2M0). Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma. The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy. Key words: computerized tomography, positron emission tomography, squamous cell anal cancer, staging, supraclavicular nodal metastasis Introduction Despite that malignancies of the anal canal are relatively rare, accounting for 4% of the lower gastrointestinal (GI) carcinomas [1-3], SCC most commonly occurs in 47-60% of these cases [4]. The risk of invasive SCC associated with poor prognosis increases 2-6 times in HIV-positive patients [5]. The probability of nodal involvement is directly related Received ; ccepted uthor and address for correspondence: Dr. Elena Piperkova 328 E 86th Street, app. PH New York, NY US Tel: elenapiperkova@yahoo.com to the main risk factors such as the tumor size, site and cell differentiation. bove the dentate line, tumor drainage flows to perirectal and paravertebral nodes and below this line drainage is through the inguinal and femoral nodes [6]. Distant extrapelvic metastases occur approximately in 10% of the patients, predominantly to the lung and liver, most commonly following the dual lymphatic drainage to the portal and systemic nodal basins [7]. ccurate staging followed with an optimal planning of radiation therapy and chemotherapy can extend the survival of the patients. The anatomical imaging techniques [CT, ultrasound (US) and/or magnetic resonance imaging (MRI)] cannot evaluate tumor biology and behavior [8]. Functional PET imaging can have a role in assessing hypermetabolic 18 F-FDG avid lesions inconclusive by the other imaging modalities [9]. In combined PET/CT, PET with 18 F-FDG is known to be sensitive enough for detecting viable tumor tissue, whereas CT permits vi-
2 524 sualization of anatomic changes and exact localization of the metabolic proliferative changes [10]. Meta et al. in their retrospective review of the impact of PET on the treatment of rectal cancer reported that it changed both the staging in 42% of the patients and treatment in more than 60% [11]. We did not find PET/CT data on SCC staging in the accessible clinical reports and any clinical reports with supraclavicular LN metastasis from SCC. The interest of this case lies in the PET/CT impact on the exact primary staging and restaging with metastatic extension including unexpected SCC supraclavicular LN metastasis, as well as on the assessment of multimodality radiochemotherapy efficacy or further treatment planning. Case presentation 45-year-old HIV-positive white male with stage II (T2N0M0) poorly differentiated SCC was diagnosed in January 2005 following diagnostic workup of anal condylomata acuminata. The surgical specimen pathology reported invasive poorly differentiated squamous cell carcinoma. Past history was significant for HIV for 12 years with several episodes of pneumonia and encephalitis. PET/ CT was requested for initial staging and restaging and was performed 80 min post-injection of the 18 F-FDG, using a PET/CT Discovery ST-General Electric Medical System. low dose x-ray CT was used for attenuation, correction and anatomical localization of the 18 F-FDG emission PET scan. The scan was performed from the mid thigh to the base of the skull. Oral contrast was given. Intravenous contrast was not used. The results of PET/CT were evaluated for primary staging, chemotherapy and RT response, restaging and planning further therapy. The primary staging PET/CT study suggested a hypermetabolic ano-rectal tumor with increased uptake of 18 F-FDG with maximum standardized uptake value (SUV max) 5.1 and regional metastasis to the left side of the pelvis, as well as to iliac LNs at the level of L4-5 with SUV max 5.3 (Figure1a,b). The resulting pretreatment PET/CT findings led to upstaging from T2N0M0 (stage II) to T2N2M0 (stage III ). Five months later after completion of combination chemotherapy with 5-fluorouracil (5-FU), mitomycin C, and cisplatin and RT to the groin/anal region, a whole body PET/CT scan was carried out to evaluate treatment response. The study demonstrated marked improvement of the hypermetabolic lesions in the ano-rectal region and pelvic LNs compared with the previous scan, suggesting good response to chemoradiotherapy (Figure 2a). Biopsies taken from the site of the primary lesion and treated regions showed squamous mucosa with hyperplastic changes and moderate to severe epithelial dysplasia without invasive carcinoma. However, evaluation of the abdomen and pelvis revealed several new foci of intense 18 F-FDG uptake with max SUV 12.0 in the left paraaortic LN chain at the level of the L2-3 vertebrae (Figure 2b). There was also enhanced 18 F-FDG uptake (max SUV 3.7) that fused to a normal sized aorto-caval LN and borderline right paraaortic LN (max SUV 3.7). Evaluation of the head and neck, other LN groups, lung parenchyma, mediastinum, both axillae, chest wall, liver and spleen revealed normal uptake of 18 F-FDG. Biopsy showed metastatic squamous cell carcinoma in a paraaortic LN. One month later a PET/CT study was requested for RT planning which showed persistent 18 F-FDG increased uptake in multiple bulky abdominal and retroperitoneal LNs with max SUV raging from 5.0 to 11.5, unchanged since the prior study. Evaluation of the head and neck showed a new low-grade focal 18 F-FDG uptake with max SUV 2.2 in a left subcentimeter supraclavicular LN (Figure 3a). This LN was not well delineated, but was worrisome for disease involvement. Diagnostic enhanced contrast CT scan revealed no significant LN metastases in the supraclavicular region bilaterally (Figure 3b). Biopsy of the mild hypermetabolic supraclavicular LN noted by PET and localized by fusion low dose x-ray CT scan showed metastatic involvement, histologically similar to the primary tumor lesion. RT was substituted by chemotherapy. Discussion Two-year survival rate is about 10% in patients with extrapelvic metastases of SCC and depends on the treatment strategy [1,12]. Daniaud-lexandre et al. in a series of 305 SCC patients reported that prompt treatment of recurrences with RT and concurrent chemotherapy, usually with 5-FU plus either mitomycin-c or cisplatin, can lead to remission in up to 25% of advanced anal carcinomas [13]. RT and chemotherapy promote an important prolongation of survival but they need accurate staging and an early treatment response evaluation [14,15]. PET/CT imaging with the glucose analogue 18 F-FDG is increasingly used to stage different malignant diseases [10,16]. Furthermore, therapy-induced
3 525 Figure 1. : PET evaluation of GI tract demonstrates increased uptake in the lower rectum with max SUV of 5.1 (black arrows). There is no tumor extension outside the rectum. In the pelvis there are multiple lymph nodes along the left pelvic sidewall demonstrating increased activity (black arrows). B: Two additional lymph nodes are seen along the left iliac artery with increased 18F-FDG uptake at the level of L4-5 with max SUV of 5.3 and fusion with an enlarged lymph node at the same location (black arrows). There is no evidence of liver, upper abdomen, pulmonary, osseous or rest of the body 18F-FDG hypermetabolic metastases. changes in tumors are related to changes in 18F-FDG uptake and treatment response can be monitored using the standardized uptake value of 18F-FDG [9]. In a comparative study by dams et al. US, CT, MRI and 18F-FDG metabolic PET image findings were evaluated in head and neck cancer [17]. Their data confirmed 90% sensitivity, 94% specificity and 93% accuracy of 18F-FDG for LN staging of squamous cell cancer of the head and neck, and respectively, 82%, 85%, 85% for CT, 80%, 79%, 79% for MRI and 72%, 70%,70% in cases where US had been used. New developments in CT, MRI, and US have improved image quality and made possible better structural lesion detection, but they lack the critical information about metabolic activity. Kalff et al. reported metastatic disease in 7% of the patients with colorectal cancer being negative before 18F-FDG-PET evaluation [18]. Relapse was confirmed in 98% (49/50) of PET-positive patients and the management plan for 56% was altered as a direct result of unexpected PET findings.18f-fdg PET imaging was more accurate (92%) than CT (71%) for
4 526 B Figure 2. : The previously seen hypermetabolic ano-rectal lesion and pelvic lymph node are not evident on the current PET study (white, black arrows). B: New foci of intense 18F-FDG uptake with max SUV 12.0 along with enlarged left paraaortic lymph nodes at the level of the L2-3 are visualized (black arrow). lso enhanced 18F-FDG uptake (max SUV 3.7) fusing to a normal sized aorto-caval and borderline right paraaortic lymph node (max SUV 3.7). extrahepatic metastases [16]. Whole body PET/CT improved the detection of lesions on both CT and 18FFDG-PET scans. In conclusion, in this clinical case, based on PET/ CT, primary stage changed from II (T2N0M0) to III (T2N2M0). The diffuse lymphadenopathy in this HIV-positive patient with SCC was distinguished from metastatic LN involvement. Subsequent fol- low up demonstrated further progression to stage IV (T2N2M1). PET/CT accurately identified treatment response and helped choose adequate treatment strategy. The unique advantage of PET/CT fusion imaging was the ability to correlate the findings of anatomic and functional imaging modalities and played a more important role than diagnostic CT alone in choosing the proper treatment.
5 527 B Figure 3. : PET/CT evaluation shows new low grade focal 18 F-FDG uptake with max SUV 2.2 in a left supraclavicular subcentimeter lymph node (arrow); B: CT scan of the neck soft tissues with contrast reveals no lymph node metastases in this region (arrow). References 1. Cummings BJ. Metastatic anal cancer: The search for cure. Oncologie 2006; 29: Greenlee RT, Muray T, Bolden S Wingo P. Cancer statistics C Cancer J Clin 2000; 50: Hwang HJ, Bestani C, Jimenez R et al. Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital. cta Gastroenterol Latinoam 2005; 35: Gervasoni JE, Wanebo HJ. Cancers of the anal canal and anal margin. Cancer Invest 2003; 21: Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004; 47: Ryan DP, Compton CC, Mater RJ. Carcinoma of the anal cancer. N Engl J Med 2000; 342: Bartelink H, Roelofson F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer:results of a phase III randomized trial of the EORTC radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997; 15: Dzik-Jurasz S. Pelvic malignancy: integrating form and function. Br J Radiol 2005; 78: Weber W. PET for response assessment in oncology: radiotherapy and chemotherapy. Br J Radiol 2005; 28 (Suppl): Ell PJ. PET/CT in oncology: a major technology for cancer care. Chang Gung Med J 2005; 28: Meta J, Seltzer M, Schiepers C et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician s perspective. J Nucl Med 2001; 42: Johnson LG, Madeleine MM, Newcomer LM Schwartz SM, Daling JR. nal cancer incidence and survival: the surveillance, epidemiology, and end results experience, Cancer 2004; 101: Deniaud-lexandre E, Touboul E, Tiret E et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal.int J Radiat Oncol Biol Phys 2003; 56: Klas JV, Rothenberger D, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment and outcomes. Cancer 1999; 85: Hung, Crane C, Delclos M et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003; 97: Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North m 2001; 39: dams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med Mol Imaging 1998; 25: Kalff V, Hicks RJ, Ware RE, Hogg, Binns D, McKenzie F. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43:
Dr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationStaging recurrent ovarian cancer with 18 FDG PET/CT
ONCOLOGY LETTERS 5: 593-597, 2013 Staging recurrent ovarian cancer with FDG PET/CT SANJA DRAGOSAVAC 1, SOPHIE DERCHAIN 2, NELSON M.G. CASERTA 3 and GUSTAVO DE SOUZA 2 1 DIMEN Medicina Nuclear and PET/CT
More informationPrognostic factors in squamous cell anal cancers
Prognostic factors in squamous cell anal cancers Zainul Abedin Kapacee Year 4-5 Intercalating Medical Student, University of Manchester Dr. Shabbir Susnerwala, Mr. Nigel Scott Dr. Falalu Danwata, Dr. Marcus
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationSTAGING AND FOLLOW-UP STRATEGIES
ATHENS 4-6 October 2018 European Society of Urogenital Radiology STAGING AND FOLLOW-UP STRATEGIES Ahmet Tuncay Turgut, MD Professor of Radiology Hacettepe University, Faculty of Medicine Ankara 2nd ESUR
More informationClinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.
Clinical summary Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT. For restaging PET/CT. PET/CT findings No significant FDG uptake
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationEsophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers
Esophageal Cancer What is the value of performing PET scan routinely for staging of esophageal cancers What is the sensitivity and specificity of PET scan for metastatic lesions When should PET scan be
More informationDisclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationCancer of Unknown Primary (CUP)
Cancer of Unknown Primary (CUP) Pathways and Guidelines V1.0 London Cancer September 2013 The following pathways and guidelines document has been compiled by the London Cancer CUP technical subgroup and
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study
Official publication of Orofacial Chronicle,India www.jhnps.weebly.com ORIGINAL ARTICLE ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study ABSTRACT: Akheel Mohammad 1, Anuj
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationProf. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.
Role of Whole-body Diffusion MR in Detection of Metastatic lesions Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C. Cancer is a potentially life-threatening disease,
More informationPET in Rectal Carcinoma
Case Report PET in Rectal Carcinoma Josefina Jofré M 1, Paulina Sierralta C 1, José Canessa G 1,2, Pamela Humeres A 3, Gabriel Castro M 4, Teresa Massardo V 1,4 1 Centro PET de Imágenes Moleculares, Hospital
More informationTHE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)
THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC) I.Kostadinova, Sofia, Bulgaria CMM some clinical facts The incidence
More informationRyan Niederkohr, M.D. Slides are not to be reproduced without permission of author
Ryan Niederkohr, M.D. CMS: PET/CT CPT CODES 78814 Limited Area (e.g., head/neck only; chest only) 78815 78816 Regional (skull base to mid-thighs) True Whole Body (skull vertex to feet) SELECTING FIELD
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationPositron emission tomography/computer tomography in the evaluation of head and neck cancer treatment
Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment Severina Šedienė 1, Ilona Kulakienė 1, Viktoras Rudžianskas 2 1 Lithuanian University of Health Sciences,
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationIMAGING GUIDELINES - COLORECTAL CANCER
IMAGING GUIDELINES - COLORECTAL CANCER DIAGNOSIS The majority of colorectal cancers are diagnosed on colonoscopy, with some being diagnosed on Ba enema, ultrasound or CT. STAGING CT chest, abdomen and
More informationWHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?
doi:10.1016/j.ijrobp.2006.12.044 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 2, pp. 383 387, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationCOLORECTAL CANCER STAGING in 2010
COLORECTAL CANCER STAGING in 2010 Robert A. Halvorsen, MD, FACR MCV Hospitals / VCU Medical Center Richmond, Virginia I do not have any relevant financial relationships with any commercial interests COLON
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationThe Proper Use of PET/CT in Tumoring Imaging
The Proper Use of PET/CT in Tumoring Imaging Mijin Yun, M.D. Jong Doo Lee, M.D. Department of Radiology / Division of Nuclear Medicine Yonsei University College of Medicine, Severance Hospital E mail :
More informationL hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?
L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active? Thierry Vander Borght UCL Mont-Godinne, Belgique FDG-PET in Lymphoma: Mont-Godinne Experience 03/2000 10/2002:
More informationRadiology Pathology Conference
Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationNavigators Lead the Way
RN Navigators Their Role in patients with Cancers of the GI tract Navigators Lead the Way Nurse Navigator Defined Nurse Navigator A clinically trained individual responsible for the identification and
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationAdvanced Pelvic Malignancy: Defining Resectability Be Aggressive. Lloyd A. Mack September 19, 2015
Advanced Pelvic Malignancy: Defining Resectability Be Aggressive Lloyd A. Mack September 19, 2015 CONFLICT OF INTEREST DECLARATION I have no conflicts of interest Advanced Pelvic Malignancies Locally Advanced
More informationLung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
More informationPET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging
Basics of PET/CT Imaging Kevin Robinson, DO Department of Radiology Michigan State University Objectives Basic PET imaging Evaluating the therapeutic response Evaluating the big 5 Lymphoma Breast Lung
More informationANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY
ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY Note: These surveillance recommendations are provided as recommendations only. Clinicians should take into account
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationImaging techniques in the diagnosis, staging and follow up of GI cancers. Moderators: Banke Agarwal, MD and Paul Schultz, MD
Imaging techniques in the diagnosis, staging and follow up of GI cancers Moderators: Banke Agarwal, MD and Paul Schultz, MD Panelists Axel Grothey, MD Professor of Oncology Division of Medical Oncology
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (4), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (4), Page 2271-2277 Role of Pet/Ct in Assessment of Post Therapeutic Hepatocellular Carcinoma Omar Hussain Omar, Mohamed Elgharib Abo Elmaaty,
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationPET-CT versus MRI in the identification of hepatic metastases from colorectal carcinoma: An evidence based review of the current literature.
PET-CT versus MRI in the identification of hepatic metastases from colorectal carcinoma: An evidence based review of the current literature. Poster No.: C-1275 Congress: ECR 2017 Type: Scientific Exhibit
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationArticle begins on next page
Scalp metastasis as a presenting symptom of Cervical Squamous Cell Carcinoma Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters. [https://rucore.libraries.rutgers.edu/rutgers-lib/50623/story/]
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationRadiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
More informationEsophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node
2012 66 5 417 421 Esophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node a b* a a a a a a a b ʼ 418 Horio et al. Acta Med. Okayama Vol.
More informationYiyan Liu. 1. Introduction
AIDS Research and Treatment Volume 2012, Article ID 764291, 6 pages doi:10.1155/2012/764291 Clinical Study Concurrent FDG Avid Nasopharyngeal Lesion and Generalized Lymphadenopathy on PET-CT Imaging Is
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationVagina. 1. Introduction. 1.1 General Information and Aetiology
Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationAlison Douglass Gillian Lieberman, MD. November. Colon Cancer. Alison Douglass, Harvard Medical School Year III Gillian Lieberman, MD
November Colon Cancer Alison Douglass, Harvard Medical School Year III Our Patient Mr. K. is a 67 year old man with no prior medical problems other than hemorrhoids which have caused occasional rectal
More informationM etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT
1270 SCIENTIFIC REPORT Whole body PET/CT for initial staging of choroidal P T Finger, M Kurli, S Reddy, L B Tena, A C Pavlick... Aim: To investigate the value of whole body positron emission tomography/computed
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationHybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD
Hybrid Imaging SPECT/CT PET/CT PET/MRI SNMMI Southwest Chapter 2014 Aaron C. Jessop, MD Assistant Professor, Department of Nuclear Medicine UT MD Anderson Cancer Center, Houston, Texas Complimentary role
More informationADI Procedure Codes. August 2016 Revised April 2017 Page 1 of 7 ADI Procedure Codes
Code Description 70450 CT Head without contrast 70460 CT Head with contrast 70470 CT Head with & without contrast 70480 CT Orbit, et al without contrast 70481 CT Orbit, et al with contrast 70482 CT Orbit,
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More informationCan we omit prophylactic inguinal nodal irradiation in anal cancer patients?
Original Article Radiat Oncol J 215;33(2):83-88 http://dx.doi.org/1.3857/roj.215.33.2.83 pissn 2234-19 eissn 2234-3156 Can we omit prophylactic inguinal nodal irradiation in anal cancer patients? Hakyoung
More informationHEAD AND NECK SQUAMOUS
ORIGINAL ARTICLE The Role of Positron Emission Tomography and Computed Tomography Fusion in the Management of Early-Stage and Advanced-Stage Primary Head and Neck Squamous Cell Carcinoma Patrick K. Ha,
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 4/30/2011 Radiology Quiz of the Week # 18 Page 1 CLINICAL PRESENTATION AND RADIOLOGY
More informationShort summary of published results of PET with fluoromethylcholine (18F) in prostate cancer
Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer JN TALBOT and all the team of Service de Médecine Nucléaire Hôpital Tenon et Université Pierre et Marie Curie,
More informationANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationHEALTHFIRST 2011 RADIOLOGY PROGRAM CODE LIST
HEALTHFIRST 2011 RADIOLOGY PROGRAM CODE LIST Outpatient Radiology utilization call Carecore at 1-877-773-6964 Modality CPT CODE Description CT SCANS 70450 CT HEAD/BRAIN W/O CONTRAST CT SCANS 70460 CT HEAD/BRAIN
More information[A RESEARCH COORDINATOR S GUIDE]
2013 COLORECTAL SURGERY GROUP Dr. Carl J. Brown Dr. Ahmer A. Karimuddin Dr. P. Terry Phang Dr. Manoj J. Raval Authored by Jennifer Lee A cartoon about colonoscopies. 1 [A RESEARCH COORDINATOR S GUIDE]
More informationHybrid bone scintigraphy in gastrointestinal malignancies Institutional Experience
Hybrid bone scintigraphy in gastrointestinal malignancies Institutional Experience Nazia Rashid 1, Saima Riaz 1, Humayun Bashir 1, Shafqat Mehmood 2 1 Nuclear Medicine Department ad 2 Internal Medicine
More informationVaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
More information05/02/ CPT Preauthorization Groupings Effective May 2, Computerized Tomography (CT) Abdomen 6. CPT Description SEGR CT01
Computerized Tomography (CT) 6 & 101 5 Upper Extremity 11 Lower Extremity 12 Head 3 Orbit 1 Sinus 2 Neck 4 7 Cervical Spine 8 Thoracic Spine 9 Lumbar Spine 10 Colon 13 CPT Preauthorization Groupings CPT
More information